189 related articles for article (PubMed ID: 17896982)
1. Design, synthesis, and structure-activity relationship study of peroxisome proliferator-activated receptor (PPAR) delta-selective ligands.
Miyachi H
Curr Med Chem; 2007; 14(22):2335-43. PubMed ID: 17896982
[TBL] [Abstract][Full Text] [Related]
2. Advances and Challenges in Drug Design of PPARδ Ligands.
Maltarollo VG; Kronenberger T; Windshugel B; Wrenger C; Trossini GHG; Honorio KM
Curr Drug Targets; 2018; 19(2):144-154. PubMed ID: 28413978
[TBL] [Abstract][Full Text] [Related]
3. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
Evans JL; Lin JJ; Goldfine ID
Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606
[TBL] [Abstract][Full Text] [Related]
4. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present).
Takada I; Makishima M
Expert Opin Ther Pat; 2020 Jan; 30(1):1-13. PubMed ID: 31825687
[No Abstract] [Full Text] [Related]
6. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
[TBL] [Abstract][Full Text] [Related]
7. [Design and synthesis of peroxisome proliferator-activated receptor (PPAR) delta agonists and its implication to the driving force to elicit PPAR delta selectivity].
Kasuga J; Oyama T; Nakagome I; Aoyama A; Sako K; Makishima M; Hirono S; Morikawa K; Hashimoto Y; Miyachi H
Yakugaku Zasshi; 2009 Jun; 129(6):709-18. PubMed ID: 19483413
[TBL] [Abstract][Full Text] [Related]
8. PPAR dual agonists: are they opening Pandora's Box?
Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
[TBL] [Abstract][Full Text] [Related]
9. Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) delta agonists.
Bratton LD; Filzen GF; Geyer A; Hoffman JK; Lu G; Pulaski J; Trivedi BK; Unangst PC; Xu X
Bioorg Med Chem Lett; 2007 Jul; 17(13):3624-9. PubMed ID: 17498950
[TBL] [Abstract][Full Text] [Related]
10. Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.
Batista FA; Trivella DB; Bernardes A; Gratieri J; Oliveira PS; Figueira AC; Webb P; Polikarpov I
PLoS One; 2012; 7(5):e33643. PubMed ID: 22606221
[TBL] [Abstract][Full Text] [Related]
11. Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Honda A; Kamata S; Akahane M; Machida Y; Uchii K; Shiiyama Y; Habu Y; Miyawaki S; Kaneko C; Oyama T; Ishii I
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563117
[TBL] [Abstract][Full Text] [Related]
12. Recent progress in research on peroxisome proliferator-activated receptor alpha-selective ligands.
Miyachi H
IDrugs; 2004 Aug; 7(8):746-54. PubMed ID: 15334308
[TBL] [Abstract][Full Text] [Related]
13. Novel Cinnamic Acid Derivatives as Potential PPARδ Agonists for Metabolic Syndrome: Design, Synthesis, Evaluation and Docking Studies.
Chauhan A; Grewal AS; Pandita D; Lather V
Curr Drug Discov Technol; 2020; 17(3):338-347. PubMed ID: 30868955
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor delta agonists.
Filzen GF; Bratton L; Cheng XM; Erasga N; Geyer A; Lee C; Lu G; Pulaski J; Sorenson RJ; Unangst PC; Trivedi BK; Xu X
Bioorg Med Chem Lett; 2007 Jul; 17(13):3630-5. PubMed ID: 17512197
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptors: from genes to physiology.
Kliewer SA; Xu HE; Lambert MH; Willson TM
Recent Prog Horm Res; 2001; 56():239-63. PubMed ID: 11237216
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Okazaki S; Shioi R; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
Bioorg Med Chem; 2016 Nov; 24(21):5455-5461. PubMed ID: 27622746
[TBL] [Abstract][Full Text] [Related]
17. Ligand- and structure-based drug design strategies and PPARδ/α selectivity.
Maltarollo VG; Honório KM
Chem Biol Drug Des; 2012 Oct; 80(4):533-44. PubMed ID: 22672760
[TBL] [Abstract][Full Text] [Related]
18. Structure-based virtual screening and discovery of New PPARδ/γ dual agonist and PPARδ and γ agonists.
Maltarollo VG; Togashi M; Nascimento AS; Honorio KM
PLoS One; 2015; 10(3):e0118790. PubMed ID: 25767888
[TBL] [Abstract][Full Text] [Related]
19. Cow's milk increases the activities of human nuclear receptors peroxisome proliferator-activated receptors alpha and delta and retinoid X receptor alpha involved in the regulation of energy homeostasis, obesity, and inflammation.
Suhara W; Koide H; Okuzawa T; Hayashi D; Hashimoto T; Kojo H
J Dairy Sci; 2009 Sep; 92(9):4180-7. PubMed ID: 19700678
[TBL] [Abstract][Full Text] [Related]
20. Targeting Peroxisome Proliferator-Activated Receptor Delta (PPARδ): A Medicinal Chemistry Perspective.
Kadayat TM; Shrestha A; Jeon YH; An H; Kim J; Cho SJ; Chin J
J Med Chem; 2020 Sep; 63(18):10109-10134. PubMed ID: 32539376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
